Next generation sequencing (NGS) may be highly beneficial in select patients with sarcoma.
The researchers conducted a retrospective cohort study of patients with advanced STS treated at a single institution over a 12 month period.
Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.
Approximately 70% of patients were administered anthracyclines as a primary therapy across patient datasets from France, Germany, Spain, and Italy.
Durable responses to treatment with atezolizumab in advanced alveolar soft part sarcoma were seen across a phase 2 study.
Responses to crizotinib in ALK+ inflammatory myofibroblastic tumors were consistent with responses in ALK+ NSCLC, according to presenter Dr Schöffski.
Australian researchers identified the gene using whole-genome sequencing in patients enrolled in the International Sarcoma Kindred Study.
Researchers observed increased real-world incidence of cardiomyopathy in patients treated with trabectedin compared with that seen in the phase 3 study of the drug.
But, there was no difference in DFS, DMFS, or OS between the 2 treatment subtypes at 5 years following the conclusion of the original study.
Study Adds More Evidence to Support Active Surveillance as the Standard of Care for Certain Desmoid TumorsNovember 16, 2018
Experts embrace the "less is more" approach to guide treatment decisions in primary sporadic desmoid tumors.
A subset of patients experienced sustained clinical benefit and at least some objective tumor response.
The switch from a continuous to an intermittent dosing schedule appeared to cut the occurrence of thrombocytopenia in half.
Researchers suggested the use of comparative oncology to identify novel therapies that could have clinical applications in osteosarcoma.
Analysis of transcriptomic data revealed that a subset of patients with these smooth muscle sarcomas have ALK fusions that retain targetable ALK kinase domains.
Patients with fascia-infiltrating sarcoma appeared to have worse survival that those who had either strict superficial or deep soft tissue sarcomas.
By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.
Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.
Epizyme released the results of its phase 2 study of tazemetostat in epithelioid sarcoma.
Results warrant further testing of nintedanib in this disease setting.
Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.
Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.
Cabozantinib demonstrated efficacy in osteosarcoma and Ewing sarcoma in 2 single-arm, phase 2 trials, with objective response rates of 45% and 58%, respectively.
A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.
Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?October 04, 2018
In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.
An open-label, single-center, phase 2 trial is underway to evaluate neoadjuvant nivolumab alone and in combination with ipilimumab in soft tissue sarcoma.
Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.
Trabectedin plus olaparib showed acceptable safety and tolerability in patients with metastatic and unresectable bone and soft-tissue sarcomas.
Researchers determined that treatment with ifosfamide in childhood sarcoma did not increase the risk of long-term nephrotoxicity.
More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.
Previous studies have suggested that high-dose therapy with busulfan plus melphalan may confer a benefit to patients with Ewing sarcoma compared with conventional chemotherapy.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified
- Gly101Val Mutation Directly Causes Resistance to Venetoclax
- Can Treatments for Childhood ALL Alter the Gut Microbiome?